Session Abstract
Session Synopsis: Adoption of genomic testing in oncology has been slow. Even when molecular testing is done, information from tests are not always used in treatment decisions, and outcomes of targeted therapy are frequently not tracked. The molecular pathologist can help to shift this paradigm by providing useful information to the oncologist at the point of care: on-label and off-label therapeutics, access to research protocols and trials, and data to support clinical decision-making. Pathologist involvement is also critical for appropriate outcomes analysis.
Session Chair Profile
CEO and Chairperson, N-of-One
Biography
Christine Cournoyer is Chief Executive Officer of N-of-One. Prior to joining N-of-One, she was President and Chief Operating Officer of Picis, a leading company in the healthcare IT market. Picis provided software solutions that bridge revenue cycle and clinical workflow management for high-acuity operations within hospitals, including emergency rooms, operating rooms, and critical care. Picis’ systems were installed in more than 1,800 medical centers, hospitals, and integrated delivery networks in 19 countries around the world. Ms. Cournoyer served as President and Chief Operating Officer of Lightbridge, Inc. and held senior management positions at IBM, including Vice President of Business Transformation as well as Chief Information Officer of IBM’s software group. She also served as Senior Vice President at Lotus Development. Ms. Cournoyer was named one of the “10 Most Influential Women in Technology” by Businessweek. She is currently a Corporator for Emerson Hospital and a member of both the Boston Club and the Women Corporate Directors.
Speaker Profile
M.D., Scientific Director, Personalized Medicine Program at the Swedish; Director of Molecular Diagnostics, CellNetix Pathology and Laboratories Institute
Biography
Dr. Anna Berry is the Scientific Director of the Personalized Medicine Program at the Swedish Cancer Institute and the Director of Molecular Diagnostics at CellNetix Pathology and Laboratories. She is a graduate of the University of Nebraska Medical Center, and completed her post-graduate training at SUNY Upstate Medical University, the Medical College of Virginia, and the National Cancer Institute. Dr. Berry is Board Certified in Molecular Genetic Pathology, Cytopathology, Anatomic Pathology and Clinical Pathology, and served previously as the Director of Molecular Pathology and the Director of the Molecular Genetic Pathology fellowship training program at UCSF. Her clinical focus is making genomic technologies accessible to patients, and integrating genomic data into patient care. She serves on several national committees, including the Personalized Healthcare Committee of the College of American Pathologists, participates in several national genomics task forces. Dr. Berry has given invited lectures and has taught CME courses at many locations across the country, as well as on-line.
